Table 5.

Incidence of long-term kidney outcomes according to initial randomization to fenofibrate versus placebo (in addition to statin therapy), stratified by sex

OutcomeaWomenMenWhite RaceNonwhite Race
n=1634 (821 Fibrate, 813 Placebo)n=3721 (1864 Fibrate, 1857 Placebon=3676 (1858 Fibrate, 1818 Placebo)n=1679 (827 Fibrate, 852 Placebo)
Event NumberHR/SHR (95% CI)Event NumberHR/SHR (95% CI)Event NumberHR/SHR (95% CI)Event NumberHR/SHR (95% CI)
Composite kidney outcome284 Feno1.32 (1.11 to 1.57)c703 Feno1.10 (0.99 to 1.22)680 Feno1.08 (0.97 to 1.20)307 Feno1.36 (1.15 to 1.61)c
232 Plac647 Plac629 Plac250 Plac
Macroalbuminuriab88 Feno1.51 (1.07 to 2.14)c212 Feno1.01 (0.82 to 1.24)
57 Plac190 Plac
Doubling of creatinine220 Feno1.82 (1.46 to 2.28)c111 Feno2.08 (1.51 to 2.86)c
121 Plac63 Plac
Dialysis31 Feno1.03 (0.61 to 1.75)67 Feno1.12 (0.76 to 1.66)
31 Plac69 Plac
All-cause mortality379 Feno
416 Plac0.88 (0.76, 1.01)152 Feno1.26 (1.0, 1.60)
128 Plac
  • HR, hazard ratio; SHR, subhazard ratio; 95% CI, 95% confidence interval; Feno, fenofibrate; Plac, placebo; —, analysis not performed because interaction term was not significant.

  • a HRs and 95% CIs are for fully adjusted multivariable analyses using contrast statements from models with participants from both subtrials.

  • b Denominators for macroalbuminuria outcome among women: 709 fenofibrate, 713 placebo; among men: 1645 fenofibrate, 1603 placebo; among whites: 1646 fenofibrate, 1587 placebo; among nonwhites: 708 fenofibrate, 729 placebo.

  • c Statistically significant results.